These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 18565301)

  • 1. [Biological treatment of rare inflammatory rheumatic diseases].
    Baslund B
    Ugeskr Laeger; 2008 Jun; 170(24):2150-2. PubMed ID: 18565301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease.
    Naumann L; Feist E; Natusch A; Langen S; Krause A; Buttgereit F; Burmester GR
    Ann Rheum Dis; 2010 Feb; 69(2):466-7. PubMed ID: 20107032
    [No Abstract]   [Full Text] [Related]  

  • 3. Blockade of interleukin 1 receptor in Still's disease affects activation of peripheral T-lymphocytes.
    Youssef J; Lazaro E; Blanco P; Viallard JF
    J Rheumatol; 2008 Dec; 35(12):2453-6. PubMed ID: 19143047
    [No Abstract]   [Full Text] [Related]  

  • 4. [Anakinra in refractory adult onset Still's disease].
    Vercoutere W; Starmans-Kool M; Peeters RM
    Ned Tijdschr Geneeskd; 2011; 155(18):A2966. PubMed ID: 21466723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F; Isenberg DA
    Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid responses to anakinra in patients with refractory adult-onset Still's disease.
    Fitzgerald AA; Leclercq SA; Yan A; Homik JE; Dinarello CA
    Arthritis Rheum; 2005 Jun; 52(6):1794-803. PubMed ID: 15934079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refractory adult onset Still's disease successfully treated with anakinra.
    Vasques Godinho FM; Parreira Santos MJ; Canas da Silva J
    Ann Rheum Dis; 2005 Apr; 64(4):647-8. PubMed ID: 15374853
    [No Abstract]   [Full Text] [Related]  

  • 8. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature.
    Kötter I; Wacker A; Koch S; Henes J; Richter C; Engel A; Günaydin I; Kanz L
    Semin Arthritis Rheum; 2007 Dec; 37(3):189-97. PubMed ID: 17583775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exacerbation of adult-onset Still's disease, possibly related to elevation of serum tumor necrosis factor-alpha after etanercept administration.
    Kaneko K; Kaburaki M; Muraoka S; Tanaka N; Yamamoto T; Kusunoki Y; Abe H; Endo H; Kawai S
    Int J Rheum Dis; 2010 Oct; 13(4):e67-9. PubMed ID: 21199457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy?
    Efthimiou P; Kontzias A; Ward CM; Ogden NS
    Nat Clin Pract Rheumatol; 2007 Jun; 3(6):328-35. PubMed ID: 17538564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade.
    Rech J; Ronneberger M; Englbrecht M; Finzel S; Katzenbeisser J; Manger K; Manger B; Schett G
    Ann Rheum Dis; 2011 Feb; 70(2):390-2. PubMed ID: 20650873
    [No Abstract]   [Full Text] [Related]  

  • 12. Pathogenesis and management of adult-onset Still's disease.
    Efthimiou P; Georgy S
    Semin Arthritis Rheum; 2006 Dec; 36(3):144-52. PubMed ID: 16949136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still's disease: the first case report.
    Benucci M; Li GF; Del Rosso A; Manfredi M
    Clin Exp Rheumatol; 2005; 23(5):733. PubMed ID: 16173267
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of thalidomide in refractory adult Still's disease: a new case report.
    Meaux-Ruault N; Magy N; Gil H; Dupond JL
    Clin Exp Rheumatol; 2003; 21(2):272. PubMed ID: 12747295
    [No Abstract]   [Full Text] [Related]  

  • 15. Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial.
    Kalliolias GD; Georgiou PE; Antonopoulos IA; Andonopoulos AP; Liossis SN
    Ann Rheum Dis; 2007 Jun; 66(6):842-3. PubMed ID: 17513574
    [No Abstract]   [Full Text] [Related]  

  • 16. Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease.
    Woo P
    Ann Rheum Dis; 2008 Mar; 67(3):281-2. PubMed ID: 18292104
    [No Abstract]   [Full Text] [Related]  

  • 17. Prolonged efficacy of infliximab for refractory adult-onset Still's disease.
    Dilhuydy MS; Vatan R; Etienne G; Longy-Boursier M; Mercié P
    Clin Exp Rheumatol; 2005; 23(1):121-2. PubMed ID: 15789901
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of adult-onset Still's disease with leflunomide and chloroquine combination in two patients.
    Pirildar T
    Clin Rheumatol; 2003 May; 22(2):157. PubMed ID: 12740686
    [No Abstract]   [Full Text] [Related]  

  • 19. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease.
    Iwamoto M; Nara H; Hirata D; Minota S; Nishimoto N; Yoshizaki K
    Arthritis Rheum; 2002 Dec; 46(12):3388-9. PubMed ID: 12483747
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.